<?xml version="1.0" encoding="UTF-8" ?>
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</dc:title>
<dc:creator>Poyatos, Lourdes</dc:creator>
<dc:creator>Papaseit Fontanet, Esther</dc:creator>
<dc:creator>Olesti Muñoz, Eulàlia, 1991-</dc:creator>
<dc:creator>Pérez Mañá, Clara</dc:creator>
<dc:creator>Ventura, Mireia</dc:creator>
<dc:creator>Carbón Mallol, Xoán</dc:creator>
<dc:creator>Grifell Guardia, Marc</dc:creator>
<dc:creator>Fonseca Casals, Francina, 1972-</dc:creator>
<dc:creator>Torrens, Marta</dc:creator>
<dc:creator>Torre Fornell, Rafael de la</dc:creator>
<dc:creator>Farré Albaladejo, Magí</dc:creator>
<dc:subject>MDMA (3,4-methylenedioxymethamphetamine)</dc:subject>
<dc:subject>Bath salts</dc:subject>
<dc:subject>Methylone (3,4-methylenedioxymethcathinone)</dc:subject>
<dc:subject>New psychoactive substances (NPS)</dc:subject>
<dc:subject>Psychostimulants</dc:subject>
<dc:subject>Synthetic cathinones</dc:subject>
<dc:description>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</dc:description>
<dc:date>2021</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</dc:identifier>
<dc:identifier>2079-7737</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/48674</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3390/biology10080788</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Biology (Basel). 2021;10(8):788</dc:relation>
<dc:rights>© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:format>application/pdf</dc:format>
<dc:publisher>MDPI</dc:publisher>
</oai_dc:dc>
<?xml version="1.0" encoding="UTF-8" ?>
<d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
<d:DIDLInfo>
<dcterms:created schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2021-10-18T06:38:01Z</dcterms:created>
</d:DIDLInfo>
<d:Item id="hdl_10230_48674">
<d:Descriptor>
<d:Statement mimeType="application/xml; charset=utf-8">
<dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10230/48674</dii:Identifier>
</d:Statement>
</d:Descriptor>
<d:Descriptor>
<d:Statement mimeType="application/xml; charset=utf-8">
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</dc:title>
<dc:creator>Poyatos, Lourdes</dc:creator>
<dc:creator>Papaseit Fontanet, Esther</dc:creator>
<dc:creator>Olesti Muñoz, Eulàlia, 1991-</dc:creator>
<dc:creator>Pérez Mañá, Clara</dc:creator>
<dc:creator>Ventura, Mireia</dc:creator>
<dc:creator>Carbón Mallol, Xoán</dc:creator>
<dc:creator>Grifell Guardia, Marc</dc:creator>
<dc:creator>Fonseca Casals, Francina, 1972-</dc:creator>
<dc:creator>Torrens, Marta</dc:creator>
<dc:creator>Torre Fornell, Rafael de la</dc:creator>
<dc:creator>Farré Albaladejo, Magí</dc:creator>
<dc:description>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</dc:description>
<dc:date>2021-10-18T06:38:01Z</dc:date>
<dc:date>2021-10-18T06:38:01Z</dc:date>
<dc:date>2021</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</dc:identifier>
<dc:identifier>2079-7737</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/48674</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3390/biology10080788</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Biology (Basel). 2021;10(8):788</dc:relation>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</dc:rights>
<dc:publisher>MDPI</dc:publisher>
</oai_dc:dc>
</d:Statement>
</d:Descriptor>
<d:Component id="10230_48674_1">
</d:Component>
</d:Item>
</d:DIDL>
<?xml version="1.0" encoding="UTF-8" ?>
<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
<dim:field element="contributor" mdschema="dc" qualifier="author">Poyatos, Lourdes</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Papaseit Fontanet, Esther</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Olesti Muñoz, Eulàlia, 1991-</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Pérez Mañá, Clara</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Ventura, Mireia</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Carbón Mallol, Xoán</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Grifell Guardia, Marc</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Fonseca Casals, Francina, 1972-</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Torrens, Marta</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Torre Fornell, Rafael de la</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Farré Albaladejo, Magí</dim:field>
<dim:field element="date" mdschema="dc" qualifier="accessioned">2021-10-18T06:38:01Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="available">2021-10-18T06:38:01Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="issued">2021</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="citation">Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="issn">2079-7737</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10230/48674</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="doi">http://dx.doi.org/10.3390/biology10080788</dim:field>
<dim:field element="description" mdschema="dc" qualifier="abstract">Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</dim:field>
<dim:field element="description" lang="en" mdschema="dc" qualifier="provenance">Made available in DSpace on 2021-10-18T06:38:01Z (GMT). No. of bitstreams: 1 Poyatos_bio_comp.pdf: 1129483 bytes, checksum: fd441164f57f781a335630118369cebf (MD5) Previous issue date: 2021</dim:field>
<dim:field element="format" mdschema="dc" qualifier="mimetype">application/pdf</dim:field>
<dim:field element="language" mdschema="dc" qualifier="iso">eng</dim:field>
<dim:field element="publisher" mdschema="dc">MDPI</dim:field>
<dim:field element="relation" mdschema="dc" qualifier="ispartof">Biology (Basel). 2021;10(8):788</dim:field>
<dim:field element="rights" mdschema="dc">© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="uri">http://creativecommons.org/licenses/by/4.0/</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="accessRights">info:eu-repo/semantics/openAccess</dim:field>
<dim:field element="title" mdschema="dc">A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</dim:field>
<dim:field element="type" mdschema="dc">info:eu-repo/semantics/article</dim:field>
<dim:field element="type" mdschema="dc" qualifier="version">info:eu-repo/semantics/publishedVersion</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">MDMA (3,4-methylenedioxymethamphetamine)</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Bath salts</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Methylone (3,4-methylenedioxymethcathinone)</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">New psychoactive substances (NPS)</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Psychostimulants</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Synthetic cathinones</dim:field>
</dim:dim>
<?xml version="1.0" encoding="UTF-8" ?>
<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
<title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</title>
<creator>Poyatos, Lourdes</creator>
<creator>Papaseit Fontanet, Esther</creator>
<creator>Olesti Muñoz, Eulàlia, 1991-</creator>
<creator>Pérez Mañá, Clara</creator>
<creator>Ventura, Mireia</creator>
<creator>Carbón Mallol, Xoán</creator>
<creator>Grifell Guardia, Marc</creator>
<creator>Fonseca Casals, Francina, 1972-</creator>
<creator>Torrens, Marta</creator>
<creator>Torre Fornell, Rafael de la</creator>
<creator>Farré Albaladejo, Magí</creator>
<description>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</description>
<date>2021-10-18</date>
<date>2021-10-18</date>
<date>2021</date>
<type>info:eu-repo/semantics/article</type>
<identifier>Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</identifier>
<identifier>2079-7737</identifier>
<identifier>http://hdl.handle.net/10230/48674</identifier>
<identifier>http://dx.doi.org/10.3390/biology10080788</identifier>
<language>eng</language>
<relation>Biology (Basel). 2021;10(8):788</relation>
<rights>http://creativecommons.org/licenses/by/4.0/</rights>
<rights>info:eu-repo/semantics/openAccess</rights>
<rights>© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</rights>
<publisher>MDPI</publisher>
</thesis>
<?xml version="1.0" encoding="UTF-8" ?>
<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<leader>00925njm 22002777a 4500</leader>
<datafield ind1=" " ind2=" " tag="042">
<subfield code="a">dc</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Poyatos, Lourdes</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Papaseit Fontanet, Esther</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Olesti Muñoz, Eulàlia, 1991-</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Pérez Mañá, Clara</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Ventura, Mireia</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Carbón Mallol, Xoán</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Grifell Guardia, Marc</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Fonseca Casals, Francina, 1972-</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Torrens, Marta</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Torre Fornell, Rafael de la</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Farré Albaladejo, Magí</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="260">
<subfield code="c">2021</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="520">
<subfield code="a">Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">2079-7737</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://hdl.handle.net/10230/48674</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://dx.doi.org/10.3390/biology10080788</subfield>
</datafield>
<datafield ind1="0" ind2="0" tag="245">
<subfield code="a">A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</subfield>
</datafield>
</record>
<?xml version="1.0" encoding="UTF-8" ?>
<mets ID=" DSpace_ITEM_10230-48674" OBJID=" hdl:10230/48674" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
<metsHdr CREATEDATE="2022-11-16T01:56:09Z">
<agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
<name>Repositori digital de la UPF</name>
</agent>
</metsHdr>
<dmdSec ID="DMD_10230_48674">
<mdWrap MDTYPE="MODS">
<xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Poyatos, Lourdes</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Papaseit Fontanet, Esther</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Olesti Muñoz, Eulàlia, 1991-</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Pérez Mañá, Clara</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Ventura, Mireia</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Carbón Mallol, Xoán</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Grifell Guardia, Marc</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Fonseca Casals, Francina, 1972-</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Torrens, Marta</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Torre Fornell, Rafael de la</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Farré Albaladejo, Magí</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2021-10-18T06:38:01Z</mods:dateAccessioned>
</mods:extension>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2021-10-18T06:38:01Z</mods:dateAvailable>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2021</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</mods:identifier>
<mods:identifier type="issn">2079-7737</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10230/48674</mods:identifier>
<mods:identifier type="doi">http://dx.doi.org/10.3390/biology10080788</mods:identifier>
<mods:abstract>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</mods:abstract>
<mods:language>
<mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</mods:accessCondition>
<mods:titleInfo>
<mods:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods>
</xmlData>
</mdWrap>
</dmdSec>
<amdSec ID="FO_10230_48674_1">
<techMD ID="TECH_O_10230_48674_1">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://repositori.upf.edu/bitstream/10230/48674/1/Poyatos_bio_comp.pdf</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>fd441164f57f781a335630118369cebf</premis:messageDigest>
</premis:fixity>
<premis:size>1129483</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>application/pdf</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>Poyatos_bio_comp.pdf</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<amdSec ID="FT_10230_48674_2">
<techMD ID="TECH_T_10230_48674_2">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://repositori.upf.edu/bitstream/10230/48674/2/Poyatos_bio_comp.pdf.txt</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>0efa1dc3b2a86c912df280ad446392cb</premis:messageDigest>
</premis:fixity>
<premis:size>70058</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>text/plain</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>Poyatos_bio_comp.pdf.txt</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<fileSec>
<fileGrp USE="ORIGINAL">
<file ADMID="FO_10230_48674_1" CHECKSUM="fd441164f57f781a335630118369cebf" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10230_48674_1" ID="BITSTREAM_ORIGINAL_10230_48674_1" MIMETYPE="application/pdf" SEQ="1" SIZE="1129483">
</file>
</fileGrp>
<fileGrp USE="TEXT">
<file ADMID="FT_10230_48674_2" CHECKSUM="0efa1dc3b2a86c912df280ad446392cb" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10230_48674_2" ID="BITSTREAM_TEXT_10230_48674_2" MIMETYPE="text/plain" SEQ="2" SIZE="70058">
</file>
</fileGrp>
</fileSec>
<structMap LABEL="DSpace Object" TYPE="LOGICAL">
<div ADMID="DMD_10230_48674" TYPE="DSpace Object Contents">
<div TYPE="DSpace BITSTREAM">
</div>
</div>
</structMap>
</mets>
<?xml version="1.0" encoding="UTF-8" ?>
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Poyatos, Lourdes</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Papaseit Fontanet, Esther</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Olesti Muñoz, Eulàlia, 1991-</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Pérez Mañá, Clara</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Ventura, Mireia</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Carbón Mallol, Xoán</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Grifell Guardia, Marc</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Fonseca Casals, Francina, 1972-</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Torrens, Marta</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Torre Fornell, Rafael de la</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Farré Albaladejo, Magí</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2021-10-18T06:38:01Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2021-10-18T06:38:01Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2021</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</mods:identifier>
<mods:identifier type="issn">2079-7737</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10230/48674</mods:identifier>
<mods:identifier type="doi">http://dx.doi.org/10.3390/biology10080788</mods:identifier>
<mods:abstract>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</mods:accessCondition>
<mods:titleInfo>
<mods:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods>
<?xml version="1.0" encoding="UTF-8" ?>
<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
<atom:id>http://oai-repositori.upf.edu/oai/metadata/handle/10230/48674/ore.xml</atom:id>
<atom:published>2021-10-18T06:38:01Z</atom:published>
<atom:updated>2021-10-18T06:38:01Z</atom:updated>
<atom:source>
<atom:generator>Repositori digital de la UPF</atom:generator>
</atom:source>
<atom:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</atom:title>
<atom:author>
<atom:name>Poyatos, Lourdes</atom:name>
</atom:author>
<atom:author>
<atom:name>Papaseit Fontanet, Esther</atom:name>
</atom:author>
<atom:author>
<atom:name>Olesti Muñoz, Eulàlia, 1991-</atom:name>
</atom:author>
<atom:author>
<atom:name>Pérez Mañá, Clara</atom:name>
</atom:author>
<atom:author>
<atom:name>Ventura, Mireia</atom:name>
</atom:author>
<atom:author>
<atom:name>Carbón Mallol, Xoán</atom:name>
</atom:author>
<atom:author>
<atom:name>Grifell Guardia, Marc</atom:name>
</atom:author>
<atom:author>
<atom:name>Fonseca Casals, Francina, 1972-</atom:name>
</atom:author>
<atom:author>
<atom:name>Torrens, Marta</atom:name>
</atom:author>
<atom:author>
<atom:name>Torre Fornell, Rafael de la</atom:name>
</atom:author>
<atom:author>
<atom:name>Farré Albaladejo, Magí</atom:name>
</atom:author>
<oreatom:triples>
<rdf:Description about="http://oai-repositori.upf.edu/oai/metadata/handle/10230/48674/ore.xml#atom">
<dcterms:modified>2021-10-18T06:38:01Z</dcterms:modified>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/48674/3/Poyatos_bio_comp.pdf.jpg">
<dcterms:description>THUMBNAIL</dcterms:description>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/48674/2/Poyatos_bio_comp.pdf.txt">
<dcterms:description>TEXT</dcterms:description>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/48674/1/Poyatos_bio_comp.pdf">
<dcterms:description>ORIGINAL</dcterms:description>
</rdf:Description>
</oreatom:triples>
</atom:entry>
<?xml version="1.0" encoding="UTF-8" ?>
<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</dc:title>
<dc:creator>Poyatos, Lourdes</dc:creator>
<dc:creator>Papaseit Fontanet, Esther</dc:creator>
<dc:creator>Olesti Muñoz, Eulàlia, 1991-</dc:creator>
<dc:creator>Pérez Mañá, Clara</dc:creator>
<dc:creator>Ventura, Mireia</dc:creator>
<dc:creator>Carbón Mallol, Xoán</dc:creator>
<dc:creator>Grifell Guardia, Marc</dc:creator>
<dc:creator>Fonseca Casals, Francina, 1972-</dc:creator>
<dc:creator>Torrens, Marta</dc:creator>
<dc:creator>Torre Fornell, Rafael de la</dc:creator>
<dc:creator>Farré Albaladejo, Magí</dc:creator>
<dcterms:abstract>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</dcterms:abstract>
<dc:date>2021</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</dc:identifier>
<dc:identifier>2079-7737</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/48674</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3390/biology10080788</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Biology (Basel). 2021;10(8):788</dc:relation>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</dc:rights>
<dc:publisher>MDPI</dc:publisher>
</qdc:qualifieddc>
<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication about="oai:repositori.upf.edu:10230/48674">
<dc:title>A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</dc:title>
<dc:creator>Poyatos, Lourdes</dc:creator>
<dc:creator>Papaseit Fontanet, Esther</dc:creator>
<dc:creator>Olesti Muñoz, Eulàlia, 1991-</dc:creator>
<dc:creator>Pérez Mañá, Clara</dc:creator>
<dc:creator>Ventura, Mireia</dc:creator>
<dc:creator>Carbón Mallol, Xoán</dc:creator>
<dc:creator>Grifell Guardia, Marc</dc:creator>
<dc:creator>Fonseca Casals, Francina, 1972-</dc:creator>
<dc:creator>Torrens, Marta</dc:creator>
<dc:creator>Torre Fornell, Rafael de la</dc:creator>
<dc:creator>Farré Albaladejo, Magí</dc:creator>
<dc:description>Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</dc:description>
<dc:date>2021</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</dc:identifier>
<dc:identifier>2079-7737</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/48674</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3390/biology10080788</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Biology (Basel). 2021;10(8):788</dc:relation>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</dc:rights>
<dc:publisher>MDPI</dc:publisher>
</ow:Publication>
</rdf:RDF>
<?xml version="1.0" encoding="UTF-8" ?>
<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
<element name="dc">
<element name="contributor">
<element name="author">
<element name="none">
<field name="value">Poyatos, Lourdes</field>
<field name="value">Papaseit Fontanet, Esther</field>
<field name="value">Olesti Muñoz, Eulàlia, 1991-</field>
<field name="value">Pérez Mañá, Clara</field>
<field name="value">Ventura, Mireia</field>
<field name="value">Carbón Mallol, Xoán</field>
<field name="value">Grifell Guardia, Marc</field>
<field name="value">Fonseca Casals, Francina, 1972-</field>
<field name="value">Torrens, Marta</field>
<field name="value">Torre Fornell, Rafael de la</field>
<field name="value">Farré Albaladejo, Magí</field>
</element>
</element>
</element>
<element name="date">
<element name="accessioned">
<element name="none">
<field name="value">2021-10-18T06:38:01Z</field>
</element>
</element>
<element name="available">
<element name="none">
<field name="value">2021-10-18T06:38:01Z</field>
</element>
</element>
<element name="issued">
<element name="none">
<field name="value">2021</field>
</element>
</element>
</element>
<element name="identifier">
<element name="citation">
<element name="none">
<field name="value">Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology (Basel). 2021;10(8):788. DOI: 10.3390/biology10080788</field>
</element>
</element>
<element name="issn">
<element name="none">
<field name="value">2079-7737</field>
</element>
</element>
<element name="uri">
<element name="none">
<field name="value">http://hdl.handle.net/10230/48674</field>
</element>
</element>
<element name="doi">
<element name="none">
<field name="value">http://dx.doi.org/10.3390/biology10080788</field>
</element>
</element>
</element>
<element name="description">
<element name="abstract">
<element name="none">
<field name="value">Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.</field>
</element>
</element>
<element name="provenance">
<element name="en">
<field name="value">Made available in DSpace on 2021-10-18T06:38:01Z (GMT). No. of bitstreams: 1 Poyatos_bio_comp.pdf: 1129483 bytes, checksum: fd441164f57f781a335630118369cebf (MD5) Previous issue date: 2021</field>
</element>
</element>
</element>
<element name="format">
<element name="mimetype">
<element name="none">
<field name="value">application/pdf</field>
</element>
</element>
</element>
<element name="language">
<element name="iso">
<element name="none">
<field name="value">eng</field>
</element>
</element>
</element>
<element name="publisher">
<element name="none">
<field name="value">MDPI</field>
</element>
</element>
<element name="relation">
<element name="ispartof">
<element name="none">
<field name="value">Biology (Basel). 2021;10(8):788</field>
</element>
</element>
</element>
<element name="rights">
<element name="none">
<field name="value">© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</field>
</element>
<element name="uri">
<element name="none">
<field name="value">http://creativecommons.org/licenses/by/4.0/</field>
</element>
</element>
<element name="accessRights">
<element name="none">
<field name="value">info:eu-repo/semantics/openAccess</field>
</element>
</element>
</element>
<element name="title">
<element name="none">
<field name="value">A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure</field>
</element>
</element>
<element name="type">
<element name="none">
<field name="value">info:eu-repo/semantics/article</field>
</element>
<element name="version">
<element name="none">
<field name="value">info:eu-repo/semantics/publishedVersion</field>
</element>
</element>
</element>
<element name="subject">
<element name="keyword">
<element name="none">
<field name="value">MDMA (3,4-methylenedioxymethamphetamine)</field>
<field name="value">Bath salts</field>
<field name="value">Methylone (3,4-methylenedioxymethcathinone)</field>
<field name="value">New psychoactive substances (NPS)</field>
<field name="value">Psychostimulants</field>
<field name="value">Synthetic cathinones</field>
</element>
</element>
</element>
</element>
<element name="bundles">
<element name="bundle">
<field name="name">THUMBNAIL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">Poyatos_bio_comp.pdf.jpg</field>
<field name="originalName">Poyatos_bio_comp.pdf.jpg</field>
<field name="description">IM Thumbnail</field>
<field name="format">image/jpeg</field>
<field name="size">37997</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/48674/3/Poyatos_bio_comp.pdf.jpg</field>
<field name="checksum">0877084d86599701decb09d4d86998c9</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">3</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">TEXT</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">Poyatos_bio_comp.pdf.txt</field>
<field name="originalName">Poyatos_bio_comp.pdf.txt</field>
<field name="description">Extracted text</field>
<field name="format">text/plain</field>
<field name="size">70058</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/48674/2/Poyatos_bio_comp.pdf.txt</field>
<field name="checksum">0efa1dc3b2a86c912df280ad446392cb</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">2</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">ORIGINAL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">Poyatos_bio_comp.pdf</field>
<field name="format">application/pdf</field>
<field name="size">1129483</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/48674/1/Poyatos_bio_comp.pdf</field>
<field name="checksum">fd441164f57f781a335630118369cebf</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">1</field>
</element>
</element>
</element>
</element>
<element name="others">
<field name="handle">10230/48674</field>
<field name="identifier">oai:repositori.upf.edu:10230/48674</field>
<field name="lastModifyDate">2021-10-19 03:31:19.381</field>
</element>
<element name="repository">
<field name="name">Repositori digital de la UPF</field>
<field name="mail">repositori@upf.edu</field>
</element>
</metadata>